Morgan Stanley Maintains Equal Weight Rating for Contineum Therapeutics

Morgan Stanley has reaffirmed its equal weight rating for shares of Contineum Therapeutics (NASDAQ: CTNM), as reported on Thursday. The investment firm has adjusted its target price for the stock to $14.00, down from a previous target of $23.00. This news comes as part of a broader analysis of the stock by various brokerages, reflecting mixed sentiments about the company’s future performance.

Several other financial institutions have issued their assessments regarding Contineum Therapeutics. On November 21, Royal Bank of Canada lowered its target price from $25.00 to $22.00 while maintaining an “outperform” rating. Meanwhile, on December 21, Wall Street Zen upgraded the stock from a “sell” rating to a “hold” rating. Additionally, Leerink Partners initiated coverage on Contineum Therapeutics on November 13, assigning an “outperform” rating and setting a target price of $22.00.

In a separate report on November 24, Robert W. Baird also reduced its target price for the company from $16.00 to $14.00, while still rating it as “outperform.” Overall, the stock has received a mixed reception, with one analyst rating it as a “strong buy,” five giving it a “buy” rating, one issuing a “hold,” and another a “sell.” According to data from MarketBeat, the consensus rating for Contineum Therapeutics stands at “moderate buy,” with an average price target of $19.00.

Stock Performance and Financial Overview

As of Thursday, shares of Contineum Therapeutics opened at $9.17. The company has a market capitalization of approximately $267.61 million, with a price-to-earnings (PE) ratio of -4.08. The stock has experienced volatility, with a 50-day moving average of $11.28 and a 200-day moving average of $9.52. Over the past year, shares have ranged from a low of $3.35 to a high of $13.57.

Contineum Therapeutics recently reported its quarterly earnings on October 30. The company revealed a loss of ($0.45) earnings per share, surpassing analysts’ expectations of ($0.58) by $0.13. Analysts predict that Contineum Therapeutics will post an average earnings per share of (-$2.01) for the current fiscal year.

Institutional Investing Trends

The stock has seen various institutional inflows and outflows recently. In the first quarter, Dynamic Technology Lab Private Ltd acquired a new stake in Contineum Therapeutics valued at $118,000. Similarly, Strs Ohio added a new position worth approximately $27,000. In the second quarter, Y Intercept Hong Kong Ltd purchased shares valued at around $140,000, while Monaco Asset Management SAM invested about $298,000. Franklin Resources Inc. also increased its stake by 7.8%, now owning 1,698,825 shares valued at approximately $6.74 million after acquiring an additional 122,644 shares.

About Contineum Therapeutics

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule therapies for issues related to neuroscience, inflammation, and immunology. Their lead product, PIPE-791, is a small molecule inhibitor targeting the lysophosphatidic acid 1 receptor (LPA1R) aimed at treating conditions such as idiopathic pulmonary fibrosis and progressive multiple sclerosis. Furthermore, the company is developing PIPE-307, a selective inhibitor for treating depression and relapsing forms of multiple sclerosis, and CTX-343, an LPA1R antagonist.

As the landscape for biopharmaceuticals evolves, Contineum Therapeutics continues to navigate the challenges and opportunities in the sector, positioning itself for future growth and advancements in therapy development.